Index -
P/E -
EPS (ttm) -4.52
Insider Own 4.13%
Shs Outstand 86.36M
Perf Week 12.24%
Market Cap 3.21B
Forward P/E -
EPS next Y -4.35
Insider Trans -3.45%
Shs Float 82.79M
Perf Month -5.29%
Income -385.66M
PEG -
EPS next Q -1.36
Inst Own 69.90%
Short Float 25.75%
Perf Quarter -6.06%
Sales 37.67M
P/S 85.33
EPS this Y -22.35%
Inst Trans 7.64%
Short Ratio 9.45
Perf Half Y -28.26%
Book/sh 21.18
P/B 1.76
EPS next Y 18.05%
ROA -16.75%
Short Interest 21.32M
Perf Year -30.49%
Cash/sh 21.52
P/C 1.73
EPS next 5Y 7.02%
ROE -19.71%
52W Range 30.04 - 67.88
Perf YTD -5.44%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -18.99%
52W High -45.17%
Beta 1.78
Dividend TTM -
Quick Ratio 15.64
Sales past 5Y 31550.17%
Gross Margin -271.64%
52W Low 23.90%
ATR (14) 2.17
Dividend Ex-Date -
Current Ratio 15.64
EPS Y/Y TTM -67.29%
Oper. Margin -1259.20%
RSI (14) 49.84
Volatility 6.65% 5.46%
Employees 393
Debt/Eq 0.12
Sales Y/Y TTM -86.13%
Profit Margin -1023.64%
Recom 1.87
Target Price 78.20
Option/Short Yes / Yes
LT Debt/Eq 0.11
EPS Q/Q -11.02%
Payout -
Rel Volume 0.89
Prev Close 37.59
Sales Surprise -86.25%
EPS Surprise -27.05%
Sales Q/Q 71.63%
Earnings May 06 AMC
Avg Volume 2.26M
Price 37.22
SMA20 -0.61%
SMA50 -3.17%
SMA200 -16.31%
Trades
Volume 2,015,548
Change -0.98%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-14-25 Upgrade
Evercore ISI
In-line → Outperform
$60 → $99
Feb-12-25 Upgrade
TD Cowen
Sell → Hold
$35
Feb-03-25 Initiated
H.C. Wainwright
Buy
$65
Aug-06-24 Reiterated
Needham
Buy
$88 → $84
Aug-02-24 Initiated
Rodman & Renshaw
Buy
$90
Jun-28-24 Resumed
Guggenheim
Neutral
Feb-15-24 Initiated
Wolfe Research
Peer Perform
Dec-11-23 Downgrade
TD Cowen
Market Perform → Underperform
$30
Oct-17-23 Downgrade
Cantor Fitzgerald
Overweight → Neutral
Sep-27-23 Initiated
Mizuho
Buy
$82
Aug-17-23 Upgrade
Citigroup
Neutral → Buy
May-30-23 Initiated
William Blair
Outperform
$75
Apr-13-23 Initiated
Cantor Fitzgerald
Overweight
$72
Mar-21-23 Initiated
Bernstein
Mkt Perform
$44
Mar-17-23 Initiated
Bryan Garnier
Buy
$70
Mar-07-23 Initiated
Robert W. Baird
Neutral
$46
Oct-11-22 Initiated
Morgan Stanley
Underweight
$37
Aug-09-22 Downgrade
Barclays
Overweight → Equal Weight
$99 → $88
Jun-23-22 Downgrade
Evercore ISI
Outperform → In-line
$66 → $60
Jun-17-22 Initiated
BMO Capital Markets
Outperform
$98
Show Previous Ratings
Today 09:00AM
07:10AM
May-12-25 06:18AM
May-10-25 05:12AM
May-08-25 11:22AM
09:30AM
Loading…
09:30AM
May-07-25 04:03PM
07:40AM
07:26AM
May-06-25 05:25PM
04:01PM
11:59AM
May-05-25 09:50AM
04:44AM
May-02-25 05:50PM
09:00AM
Loading…
09:00AM
Apr-30-25 05:14AM
Apr-29-25 07:51AM
Apr-25-25 11:59AM
Apr-24-25 05:50PM
04:11PM
Apr-23-25 06:00PM
08:33AM
Apr-21-25 09:00AM
Apr-20-25 09:15AM
Apr-17-25 06:00PM
Apr-12-25 02:45PM
Apr-11-25 03:45AM
Apr-10-25 05:50PM
Apr-09-25 09:00AM
03:29PM
Loading…
Apr-08-25 03:29PM
Apr-07-25 08:09AM
07:30AM
Apr-04-25 05:50PM
Apr-03-25 09:30AM
08:00AM
Apr-01-25 11:50AM
07:23AM
Mar-31-25 04:12PM
(Investor's Business Daily) -8.00%
03:25PM
10:10AM
09:45AM
(Investor's Business Daily)
09:03AM
Mar-28-25 09:39AM
07:01AM
Mar-26-25 04:01PM
Mar-25-25 05:40PM
11:03AM
09:00AM
Mar-22-25 04:04PM
Mar-21-25 05:50PM
08:00AM
(Investor's Business Daily)
Mar-20-25 06:00PM
02:59AM
Mar-19-25 06:10PM
02:39PM
10:27AM
09:41AM
Mar-18-25 10:41AM
Mar-14-25 09:00AM
Mar-13-25 11:30AM
Mar-11-25 08:35AM
(Pharmaceutical Technology)
Mar-03-25 09:00AM
Feb-28-25 03:15AM
Feb-26-25 08:00AM
Feb-24-25 10:00AM
Feb-23-25 01:34PM
Feb-20-25 12:01PM
09:00AM
Feb-16-25 05:34AM
Feb-15-25 02:00AM
Feb-14-25 12:20PM
10:38AM
Feb-12-25 06:37PM
11:26AM
10:25AM
Feb-11-25 05:10PM
04:01PM
Feb-10-25 05:50PM
06:15AM
Feb-06-25 08:13PM
Feb-04-25 06:00PM
Jan-30-25 01:50PM
Jan-29-25 05:50PM
08:00AM
Jan-24-25 06:00PM
Jan-23-25 08:30AM
04:15AM
Jan-17-25 11:16AM
Jan-16-25 08:00AM
03:15AM
Jan-14-25 06:00PM
04:34AM
Jan-13-25 07:00AM
Jan-09-25 04:20AM
Jan-08-25 08:30AM
Jan-07-25 06:00PM
08:00AM
07:19AM
Dec-31-24 05:50PM
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Kulkarni Samarth Chief Executive Officer Mar 21 '25 Sale 41.23 10,031 413,578 195,085 Mar 24 05:35 PM Bruno Julianne Chief Operating Officer Mar 21 '25 Sale 41.23 1,714 70,668 10,544 Mar 24 05:35 PM Prasad Raju Chief Financial Officer Mar 21 '25 Sale 41.23 2,197 90,582 16,767 Mar 24 05:35 PM KASINGER JAMES R. General Counsel and Secretary Mar 21 '25 Sale 41.23 3,185 131,318 81,729 Mar 24 05:35 PM Prasad Raju Chief Financial Officer Mar 17 '25 Sale 41.80 3,762 157,252 12,714 Mar 18 05:35 PM Kulkarni Samarth Chief Executive Officer Mar 11 '25 Sale 42.42 9,973 423,055 180,890 Mar 12 07:05 PM Kulkarni Samarth Chief Executive Officer Mar 12 '25 Sale 43.32 4,462 193,294 185,428 Mar 12 07:05 PM KASINGER JAMES R. General Counsel and Secretary Mar 11 '25 Sale 42.42 2,850 120,897 77,530 Mar 12 07:05 PM KASINGER JAMES R. General Counsel and Secretary Mar 12 '25 Sale 43.32 1,116 48,345 78,664 Mar 12 07:05 PM Bruno Julianne Chief Operating Officer Mar 11 '25 Sale 42.42 1,198 50,819 8,263 Mar 12 07:05 PM Bruno Julianne Chief Operating Officer Mar 12 '25 Sale 43.32 190 8,231 8,508 Mar 12 07:05 PM Greene John Director Feb 26 '25 Buy 44.85 7,000 313,948 7,000 Feb 28 05:35 PM Kulkarni Samarth Chief Executive Officer Feb 19 '25 Sale 55.20 18,360 1,013,564 171,613 Feb 21 05:35 PM Kulkarni Samarth Chief Executive Officer Feb 18 '25 Sale 55.05 11,640 640,782 196,901 Feb 19 05:35 PM Kulkarni Samarth Chief Executive Officer Feb 19 '25 Sale 52.80 6,928 365,798 189,973 Feb 19 05:35 PM Bruno Julianne Chief Operating Officer Feb 19 '25 Sale 52.80 333 17,582 7,062 Feb 19 05:35 PM KASINGER JAMES R. General Counsel and Secretary Feb 18 '25 Sale 53.85 9,595 516,691 73,002 Feb 19 05:35 PM KASINGER JAMES R. General Counsel and Secretary Feb 19 '25 Sale 52.80 1,947 102,802 74,880 Feb 19 05:35 PM Samarth Kulkarni Officer Feb 18 '25 Proposed Sale 52.22 45,000 2,349,900 Feb 18 05:35 PM Kulkarni Samarth Chief Executive Officer Dec 24 '24 Option Exercise 16.21 13,751 222,904 195,291 Dec 27 05:35 PM Kulkarni Samarth Chief Executive Officer Dec 02 '24 Sale 55.10 15,000 826,564 181,540 Dec 04 05:35 PM Kulkarni Samarth Chief Executive Officer Nov 11 '24 Sale 55.62 30,000 1,668,678 196,540 Nov 13 05:35 PM KASINGER JAMES R. General Counsel and Secretary Oct 14 '24 Sale 46.28 1,089 50,399 62,597 Oct 15 06:00 PM Kulkarni Samarth Chief Executive Officer Oct 14 '24 Sale 46.28 4,293 198,680 226,540 Oct 15 06:00 PM Bruno Julianne Chief Operating Officer Jun 21 '24 Sale 56.09 3,366 188,799 6,745 Jun 24 05:35 PM